Snapshot from Aug 15, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Leqembi Q2 2026 sales 29.3B yen
Business earnings release

Leqembi Q2 2026 sales 29.3B yen

Analysis based on 6 articles · First reported Jul 29, 2026 · Last updated Jul 29, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The strong sales growth of Leqembi, especially excluding the prior year's stockpiling effect, signals increasing adoption of the Alzheimer's drug. This positively impacts BioArctic's royalty revenue and may boost investor sentiment for BioArctic, Eisai, and Biogen.

Biotechnology Pharmaceuticals
Event Summary

On July 29, 2026, BioArctic's partner Eisai published preliminary global revenue for Leqembi (lecanemab) for Q2 2026, in conjunction with Biogen's Q2 report. Total sales were JPY 29.3 billion, resulting in a royalty to BioArctic of SEK 179 million, a 10% increase over Q2 2025. Excluding a one-time stockpiling effect in China in Q2 2025, royalty revenues grew approximately 43% year-over-year. Leqembi is approved in 53 countries and under review in 6. BioArctic will publish its Q2 2026 report on August 26, 2026.

Key Actions
90 BioArctic recorded royalty
80 Eisai published preliminary revenue
Entities Involved
stock
BioArctic
BioArctic receives royalties from Leqembi sales; Q2 2026 royalty of SEK 179 million represents 10% growth, boosting revenue outlook.
Importance 100.0 Sentiment 60.0
stock
Eisai
Eisai reported Leqembi sales of JPY 29.3 billion in Q2 2026, driving its revenue and partnership with Biogen.
Importance 90.0 Sentiment 50.0
stock
Biogen
Biogen is a partner in Leqembi commercialization; the sales results contribute to its Q2 2026 report.
Importance 70.0 Sentiment 40.0
cnt
China
China market had a stockpiling effect in Q2 2025; Leqembi included in Commercial Insurance Innovative Drug List in Dec 2025, supporting future sales.
Importance 30.0 Sentiment 20.0
cnt
United States
Leqembi is approved in the US; subcutaneous formulation approved as Leqembi Iqlik.
Importance 20.0 Sentiment 10.0
cnt
Japan
Leqembi approved in Japan; subcutaneous formulation application submitted in Nov 2025.
Importance 20.0 Sentiment 10.0
govactor
United States — Social Security Administration
NHSA included Leqembi in Commercial Insurance Innovative Drug List in Dec 2025, aiding market access in China.
Importance 20.0 Sentiment 10.0
curr
Japan — Japanese yen
Sales are denominated in JPY; no direct impact on the currency.
Importance 10.0 Sentiment 0.0
curr
Sweden — Swedish krona
Royalty is denominated in SEK; no direct impact on the currency.
Importance 10.0 Sentiment 0.0
cnt
United Kingdom
Leqembi is approved in the UK; no specific impact from this report.
Importance 10.0 Sentiment 0.0
govactor
United States — National Institute on Aging
Funds the AHEAD 3-45 study; no direct impact from this report.
Importance 10.0 Sentiment 0.0
govactor
United States — National Institutes of Health
Parent of United States — National Institute on Aging; no direct impact.
Importance 10.0 Sentiment 0.0
ngo
Alzheimer s Clinical Trial Consortium
Partner in AHEAD 3-45 study; no direct impact.
Importance 10.0 Sentiment 0.0
ngo
Dominantly Inherited Alzheimer Network Trials Unit
Conducts Tau NexGen study; no direct impact.
Importance 10.0 Sentiment 0.0
exch
Nasdaq Stockholm
BioArctic's B share is listed on Nasdaq Stockholm Large Cap; no direct impact.
Importance 10.0 Sentiment 0.0
Relationships
BioArctic licensor ↔ Eisai BioArctic is a research-based biopharma company that licenses its proprietary technologies and drug candidates, includin
BioArctic related ↔ Biogen
Eisai related ↔ Biogen
Eisai related ↔ China
Eisai related ↔ United States
Eisai related ↔ Japan
Biogen related ↔ United States
China strategic rivals ↔ United States China views the United States as a strategic rival, characterized by ongoing trade disputes, technological competition,
China rivals ↔ Japan China views Japan as a strategic rival, actively challenging its stance on Taiwan and territorial claims. China has impo
China related ↔ United States — Social Security Administration
China related ↔ United Kingdom
United States ally ↔ Japan The United States considers Japan a cornerstone defense ally and a vital economic partner in the Indo-Pacific, with exte
United States related ↔ United States — Social Security Administration
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
Japan related ↔ United Kingdom
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.